Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration
<p>Abstract</p> <p>Background</p> <p>Intravitreal ranibizumab prevents vision loss and improves visual acuity in patients with neovascular age-related macular degeneration, but it is expensive, and efficacy beyond 2 years is uncertain.</p> <p>Methods</p&g...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2008-06-01
|
| Series: | Cost Effectiveness and Resource Allocation |
| Online Access: | http://www.resource-allocation.com/content/6/1/12 |